Security
Amanat Acquisition Corp Class A Ordinary Shares · AMAN
AMANNASDAQCommon stockCurrentCIK 2112457Updated Oct 28, 2026
AMAN price & chart
Loading TradingView…
NASDAQ:AMAN on TradingView ↗About the company
We are a blank check company incorporated on January 13, 2026, as a Cayman Islands exempted company with limited liability for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare-related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value.
In the news
No coverage from other publishers is available.
Recent filings
425 filing
425 filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 3.02, 7.01, 9.01
10-Q filing
SCHEDULE 13D/A - filed by Amanat Sponsor Holdings LLC regarding Amanat Acquisition Corp.
Show 5 more recent filings
Offerings
Registration 333-295170
- Gross proceeds
- 75000000.0
- Net proceeds
- 72000000.0
- Deal price
- 10.0
- Shares
- 7500000
- Offering amount
- $75,000,000
- Offering price
- $10.00
- Ticker
- AMAN
Underwriters: Leerink Partners LLC
Filing attachments
ea030895401ex99-1.htm · 425 · 2026-10-26
Exhibit 99.1 Corxel US and Amanat Acquisition Corp Announce Definitive Business Combination Agreement to Create Publicly Listed Obesity-Focused Biopharmaceutical Company Combined company expected to advance differentiated oral obesity franchise led by CX11, a clinical-stage, once-daily oral small-molecule GLP-1 receptor agonist (“RA”), and CX12, a preclinical oral small-molecule amylin receptor agonist. CX11 has demonstrated clinically meaningful weight loss and a generally favora…
Read attachment ↗ea030895401ex99-2.htm · 425 · 2026-10-26
Exhibit 99.2 Oct 2026 Developing Innovative Cardiometabolic Therapies Globally STRICTLY CONFIDENTIAL 2 Disclaimer (1/2) This presentation (together with oral statements made in connection herewith, this "Presentation") is provided for informational purposes only. This Presentation has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination between Corxel Pharmaceuticals, Inc. ("Corxel" or the "Company") and Amanat Acquisition C…
Read attachment ↗ea030895401ex99-1.htm · 8-K · 2026-10-26
Exhibit 99.1 Corxel US and Amanat Acquisition Corp Announce Definitive Business Combination Agreement to Create Publicly Listed Obesity-Focused Biopharmaceutical Company Combined company expected to advance differentiated oral obesity franchise led by CX11, a clinical-stage, once-daily oral small-molecule GLP-1 receptor agonist (“RA”), and CX12, a preclinical oral small-molecule amylin receptor agonist. CX11 has demonstrated clinically meaningful weight loss and a generally favora…
Read attachment ↗ea030895401ex99-2.htm · 8-K · 2026-10-26
Exhibit 99.2 Oct 2026 Developing Innovative Cardiometabolic Therapies Globally STRICTLY CONFIDENTIAL 2 Disclaimer (1/2) This presentation (together with oral statements made in connection herewith, this "Presentation") is provided for informational purposes only. This Presentation has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination between Corxel Pharmaceuticals, Inc. ("Corxel" or the "Company") and Amanat Acquisition C…
Read attachment ↗ea029211701ex99-1.htm · 8-K · 2026-05-27
EX-99.1 2 ea029211701ex99-1.htm BALANCE SHEET DATED MAY 20, 2026 Exhibit 99.1 AMANAT ACQUISITION CORP INDEX TO FINANCIAL STATEMENT Page Financial Statement of Amanat Acquisition Corp: Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of May 20, 2026 F-3 Notes to Financial Statement F-4 F-1 REPORT OF INDEPENDENT REGISTERED PUBLI…
Read attachment ↗ea029177601ex99-1.htm · 8-K · 2026-05-21
EX-99.1 9 ea029177601ex99-1.htm PRESS RELEASE, DATED MAY 19, 2026 Exhibit 99.1 Amanat Acquisition Corp Announces Pricing of $75 Million Initial Public Offering Westfield, New Jersey, United States, May 19, 2026 (GLOBE NEWSWIRE) - Amanat Acquisition Corp (the “Company”), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today announced the pricing of its initial public offering of 7,500,000 Class A ordinary shares at an offering price of $10.…
Read attachment ↗